This study is conducted in Europe. The aim of this observational study is to evaluate glycaemic control in subjects with type 2 diabetes using once daily Levemir® as initiation of insulin therapy in Hungary.

Inclusion Criteria:

• Patient with type 2 diabetes inadequately controlled by OAD therapy based on the discretion of individual physician
• Patient willing to sign informed consent
• Particular attention should be paid to age limits, indications and contraindications and the drug interactions that are listed within the product labels

Exclusion Criteria:

• Subjects with diagnosed type 1 diabetes mellitus
• Subjects who are unlikely to comply with observational plan, (e.g., uncooperative attitude, inability to return for further visits)
• Subjects with hypersensitivity to Levemir® or to any of the ingredients
• Women of childbearing potential, who are pregnant, breast-feeding or intend to become pregnant within next 12 months.

A non-randomised sample of approximately 1000 subjects with OAD failure from specialists - diabetologists practice who have been deemed appropriate to receive insulin detemir as add-on to OAD therapy as part of routine out-patient care by the prescribing physician.